# To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects

> **NCT05363839** · PHASE1 · TERMINATED · sponsor: **Syneos Health** · enrollment: 8 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ACH-000029
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05363839
- **Lead sponsor:** Syneos Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-06
- **Primary completion:** 2022-11-02
- **Final completion:** 2022-11-02
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Based on the unblinded clinical data, the trial was terminated.
- **Last updated:** 2023-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05363839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05363839, "To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT05363839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*